{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:57:56Z","timestamp":1790985476098,"version":"4.1.0"},"reference-count":216,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,26]],"date-time":"2023-08-26T00:00:00Z","timestamp":1693008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jaci.2023.08.017","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T11:41:45Z","timestamp":1692963705000},"page":"879-893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["Neuroimmune interplay during type 2 inflammation: Symptoms, mechanisms, and therapeutic targets in atopic diseases"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8100-7161","authenticated-orcid":false,"given":"Brian","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc E.","family":"Rothenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Bachert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Artis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raza","family":"Zaheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamo","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Cyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2023.08.017_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2023.08.017_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.immuni.2023.03.015","article-title":"Modes of type 2 immune response initiation","volume":"56","author":"Kopp","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2023.08.017_bib4","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.immuni.2023.03.014","article-title":"The ins and outs of innate and adaptive type 2 immunity","volume":"56","author":"Molofsky","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2023.08.017_bib5","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/cea.13954","article-title":"Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases","volume":"51","author":"Hamilton","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2023.08.017_bib6","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc\u2019h","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2023.08.017_bib7","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2567.2007.02705.x","article-title":"Neuropeptides activate human mast cell degranulation and chemokine production","volume":"123","author":"Kulka","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.jaci.2023.08.017_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1600-0560.1998.tb01718.x","article-title":"Histamine-containing mast cells and their relationship to NGFr-immunoreactive nerves in prurigo nodularis: a reappraisal","volume":"25","author":"Liang","year":"1998","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaci.2023.08.017_bib9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.alit.2022.04.003","article-title":"Peripheral itch sensitization in atopic dermatitis","volume":"71","author":"Tominaga","year":"2022","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2023.08.017_bib11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/vaccines9030303","article-title":"Pruritus as a distinctive feature of type 2 inflammation","volume":"9","author":"Garcovich","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jaci.2023.08.017_bib12","article-title":"Roles of calcitonin gene-related peptide in the skin, and other physiological and pathophysiological functions","volume":"18","author":"Kim","year":"2021","journal-title":"Brain Behav Immun Health"},{"key":"10.1016\/j.jaci.2023.08.017_bib13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cell.2020.12.033","article-title":"A basophil-neuronal axis promotes itch","volume":"184","author":"Wang","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2023.08.017_bib14","doi-asserted-by":"crossref","first-page":"E7572","DOI":"10.1073\/pnas.1606608113","article-title":"IL-33\/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy","volume":"113","author":"Liu","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2023.08.017_bib15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2023.08.017_bib16","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jaci.2021.09.014","article-title":"IL-33 signaling in sensory neurons promoted dry skin itch","volume":"149","author":"Trier","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib17","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti\u2013thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2023.08.017_bib19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib20","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomized, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.08.017_bib21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjd.17791","article-title":"Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials","volume":"181","author":"Silverberg","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib22","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.08.017_bib23","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","article-title":"Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)","volume":"94","author":"Tha\u00e7i","year":"2019","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2023.08.017_bib24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib25","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib26","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children ages 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.08.017_bib27","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J. Allergy Clin. Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib29","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjd.20832","article-title":"Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)","volume":"186","author":"Gutermuth","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib30","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib31","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib32","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis. A\u00a0phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib33","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","article-title":"Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis","volume":"388","author":"Silverberg","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.08.017_bib34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib35","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.20873","article-title":"Nemolizumab JP01 and JP02 Study Group. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies","volume":"186","author":"Kabashima","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib36","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis","volume":"382","author":"St\u00e4nder","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.08.017_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2023.100195","article-title":"Optimal use of Jak inhibitors and biologics for atopic dermatitis on the basis of the current evidence","volume":"3","author":"Kamata","year":"2023","journal-title":"JID Innov"},{"key":"10.1016\/j.jaci.2023.08.017_bib38","first-page":"1432","article-title":"Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options","volume":"36","author":"Bieber","year":"2022","journal-title":"JEADV"},{"key":"10.1016\/j.jaci.2023.08.017_bib39","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1002\/ski2.133","article-title":"Oral Janus kinase inhibitors in the treatment of atopic dermatitis: A\u00a0systematic review and meta-analysis","volume":"3","author":"Lee","year":"2023","journal-title":"Skin Health Dis"},{"key":"10.1016\/j.jaci.2023.08.017_bib40","article-title":"Efficacy of topical and systemic treatments for atopic dermatitis on pruritus: A\u00a0systematic literature review and meta-analysis","volume":"9","author":"Rodriguez-Roy","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.jaci.2023.08.017_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1068260","article-title":"JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib42","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jdermsci.2010.03.020","article-title":"Low density of sympathetic nerve fibers relative to substance P-positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis","volume":"58","author":"Haas","year":"2010","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2023.08.017_bib43","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1034\/j.1600-0560.2000.027007359.x","article-title":"CGRP-immunoreactive nerves in prurigo nodularis\u2014an exploration of neurogenic inflammation","volume":"27","author":"Liang","year":"2000","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaci.2023.08.017_bib44","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jaad.2020.04.182","article-title":"Prurigo nodularis: pathogenesis and management","volume":"83","author":"Williams","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib45","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2133.1992.tb00452.x","article-title":"Increased sensory neuropeptides in nodular prurigo: a quantitative immunohistochemical analysis","volume":"127","author":"Molina","year":"1992","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib46","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI124609","article-title":"Neuro-immune crosstalk and allergic inflammation","volume":"129","author":"Kabata","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2023.08.017_bib47","doi-asserted-by":"crossref","first-page":"286","DOI":"10.5114\/pdia.2013.38357","article-title":"Neurogenic markers of the inflammatory process in atopic dermatitis: relation to the severity and pruritus","volume":"30","author":"Teresiak-Miko\u0142ajczak","year":"2013","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.jaci.2023.08.017_bib48","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaci.2019.06.016","article-title":"Clinical Review: Pruritus in allergy and immunology","volume":"144","author":"Yang","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib49","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/exd.14279","article-title":"Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta","volume":"30","author":"Hashimoto","year":"2021","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib50","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jaci.2013.03.050","article-title":"Human IL-31 is induced by IL-4 and promotes Th2-driven inflammation","volume":"132","author":"Stott","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib51","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2023.08.017_bib52","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1111\/jdv.18377","article-title":"Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances","volume":"36","author":"St\u00e4nder","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2023.08.017_bib53","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1172\/JCI25423","article-title":"Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction","volume":"116","author":"Fryer","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2023.08.017_bib54","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1126\/science.282.5397.2261","article-title":"Requirement for IL-13 independently of IL-4 in experimental asthma","volume":"282","author":"Grunig","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jaci.2023.08.017_bib55","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1126\/science.282.5397.2258","article-title":"Interleukin-13: central mediator of allergic asthma","volume":"282","author":"Wills-Karp","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jaci.2023.08.017_bib56","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jaci.2019.10.037","article-title":"IL-13 and IL-4, but not IL-5 nor IL-17A, induce hyperresponsiveness in isolated human small airways","volume":"145","author":"Manson","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib57","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1056\/NEJMoa012705","article-title":"Mast-cell infiltration of airway smooth muscle in asthma","volume":"346","author":"Brightling","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.08.017_bib58","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1113\/jphysiol.2009.173054","article-title":"Mast cell-cholinergic nerve interaction in mouse airways","volume":"587","author":"Weigand","year":"2009","journal-title":"J Physiol"},{"key":"10.1016\/j.jaci.2023.08.017_bib59","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nature23676","article-title":"The neuropeptide neuromedin U stimulates innate lymphoid cells and type 2 inflammation","volume":"549","author":"Klose","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2023.08.017_bib60","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature23469","article-title":"Neuronal regulation of type 2 innate lymphoid cells via neuromedin U","volume":"549","author":"Cardoso","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2023.08.017_bib61","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.immuni.2020.10.001","article-title":"Substance P release by sensory neurons triggers dendritic cell migration and initiates the type-2 immune response to allergens","volume":"53","author":"Perner","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2023.08.017_bib62","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1126\/science.aan4829","article-title":"\u03b22-adrenergic receptor-mediated negative regulation of group 2 innate lymphoid cell responses","volume":"359","author":"Moriyama","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jaci.2023.08.017_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan8546","article-title":"Pulmonary neuroendocrine cells amplify allergic asthma responses","volume":"360","author":"Sui","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jaci.2023.08.017_bib64","doi-asserted-by":"crossref","first-page":"AB128","DOI":"10.1016\/j.jaci.2022.12.403","article-title":"Interleukin 4 directly activates olfactory neurons and induces loss of smell in mice","volume":"151","author":"Hara","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib65","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/all.13559","article-title":"Type 2\/Th2-driven inflammation impairs olfactory sensory neurogenesis in mouse chronic rhinosinusitis model","volume":"74","author":"Rouyar","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2023.08.017_bib66","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11882-020-00981-x","article-title":"A TRiP through the roles of transient receptor potential cation channels in type 2 upper airway inflammation","volume":"21","author":"Backaert","year":"2021","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaci.2023.08.017_bib67","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1016\/j.cell.2021.05.017","article-title":"Sneezing reflex is mediated by a peptidergic pathway from nose to brainstem","volume":"184","author":"Li","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2023.08.017_bib68","doi-asserted-by":"crossref","first-page":"148","DOI":"10.18632\/oncotarget.6653","article-title":"The role of TRPV1 in the CD4+ T cell-mediated inflammatory response of allergic rhinitis","volume":"7","author":"Samivel","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaci.2023.08.017_bib69","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.3390\/molecules26133929","article-title":"Capsaicin-sensitive vagal afferent nerve-mediated interoceptive signals in the esophagus","volume":"26","author":"Yu","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.jaci.2023.08.017_bib70","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1053\/j.gastro.2017.06.065","article-title":"Pathophysiology of eosinophilic esophagitis","volume":"154","author":"O\u2019Shea","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2023.08.017_bib71","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4291\/wjgp.v2.i5.72","article-title":"Cytokine-induced alterations of gastrointestinal motility in gastrointestinal disorders","volume":"2","author":"Akiho","year":"2011","journal-title":"World J Gastrointest Pathophysiol"},{"key":"10.1016\/j.jaci.2023.08.017_bib72","doi-asserted-by":"crossref","first-page":"G149","DOI":"10.1152\/ajpgi.00097.2014","article-title":"Increased acid responsiveness in vagal sensory neurons in a guinea pig model of eosinophilic esophagitis","volume":"307","author":"Hu","year":"2014","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jaci.2023.08.017_bib73","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1111\/all.15260","article-title":"Mast cell-pain connection in eosinophilic esophagitis","volume":"77","author":"Zhang","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2023.08.017_bib74","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/exd.14034","article-title":"Interleukin-4 and interleukin-13 evoke scratching behaviour in mice","volume":"28","author":"Campion","year":"2019","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib75","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.neuron.2015.06.007","article-title":"Silencing nociceptor neurons reduces allergic airway inflammation","volume":"87","author":"Talbot","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.jaci.2023.08.017_bib76","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/sj.jid.5700858","article-title":"CGRP, PACAP, and VIP modulate Langerhans cell function by inhibiting NF-kappaB activation","volume":"127","author":"Ding","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib77","doi-asserted-by":"crossref","first-page":"6020","DOI":"10.4049\/jimmunol.181.9.6020","article-title":"Calcitonin gene-related peptide biases Langerhans cells toward Th2-type immunity","volume":"181","author":"Ding","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib78","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.4049\/jimmunol.1500303","article-title":"Calcitonin gene-related peptide-exposed endothelial cells bias antigen presentation to CD4+ T cells toward a Th17 response","volume":"196","author":"Ding","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecoenv.2022.114000","article-title":"Ambient ozone, and urban PM2.5 co-exposure, aggravate allergic asthma via transient receptor potential vanilloid 1-mediated neurogenic inflammation","volume":"243","author":"Lian","year":"2022","journal-title":"Ecotoxicol Environ Saf"},{"key":"10.1016\/j.jaci.2023.08.017_bib80","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/s41590-019-0493-z","article-title":"House dust mites activate nociceptor-mast cell clusters to drive type 2 skin inflammation","volume":"20","author":"Serhan","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib81","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s004280050179","article-title":"Cutaneous nerves in atopic dermatitis. A\u00a0histological, immunohistochemical and electron microscopic study","volume":"432","author":"Urashima","year":"1998","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jaci.2023.08.017_bib82","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2016.02.020","article-title":"The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves","volume":"138","author":"Feld","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib83","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1165\/rcmb.2019-0214OC","article-title":"IL-5 exposures in utero increases lung nerve density and airway reactivity in adult offspring","volume":"62","author":"Lebold","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jaci.2023.08.017_bib84","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.it.2018.10.001","article-title":"The itch-scratch cycle: a neuroimmune perspective","volume":"39","author":"Mack","year":"2018","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib85","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/exd.13972","article-title":"How to define chronic prurigo?","volume":"28","author":"Pereira","year":"2019","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib86","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jid.2017.01.030","article-title":"Increased risk of cutaneous and systemic infections in atopic dermatitis\u2014a cohort study","volume":"137","author":"Langan","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib87","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.08.017_bib88","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.anai.2017.10.019","article-title":"Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults","volume":"120","author":"Narla","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib89","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s12016-016-8548-5","article-title":"Bacterial and viral infections in atopic dermatitis: a comprehensive review","volume":"51","author":"Ong","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib90","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaad.2018.11.028","article-title":"Association between atopic dermatitis and extracutaneous bacterial and mycobacterial infections: a systematic review and meta-analysis","volume":"80","author":"Serrano","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib91","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1600-0560.1979.tb01161.x","article-title":"Prurigo nodularis: a reappraisal of the clinical and histologic features","volume":"6","author":"Doyle","year":"1979","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaci.2023.08.017_bib92","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaad.2020.07.025","article-title":"Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus","volume":"84","author":"Elmariah","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib93","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaci.2018.09.005","article-title":"Itch: from mechanism to (novel) therapeutic approaches","volume":"142","author":"Yosipovitch","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib94","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41586-022-04860-5","article-title":"PIEZO1 transduces mechanical itch in mice","volume":"607","author":"Hill","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2023.08.017_bib95","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/hmg\/ddx036","article-title":"GWAS of self-reported mosquito bite size, itch intensity and attractiveness to mosquitoes implicates immune-related predisposition loci","volume":"26","author":"Jones","year":"2017","journal-title":"Hum Mol Gen"},{"key":"10.1016\/j.jaci.2023.08.017_bib96","article-title":"The CysLT2R receptor mediates leukotriene C4-driven acute and chronic itch","volume":"118","author":"Voisin","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2023.08.017_bib97","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe3037","article-title":"Oncostatin M can sensitize sensory neurons in inflammatory pruritus","volume":"13","author":"Tseng","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2023.08.017_bib98","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.immuni.2019.03.013","article-title":"Activation of mast-cell-expressed mas-related G-protein-coupled receptors drives non-histaminergic itch","volume":"50","author":"Meixiong","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2023.08.017_bib99","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nn.2789","article-title":"TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch","volume":"14","author":"Wilson","year":"2011","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.jaci.2023.08.017_bib100","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/nn.3289","article-title":"A subpopulation of nociceptors specifically linked to itch","volume":"16","author":"Han","year":"2013","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.jaci.2023.08.017_bib101","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jaci.2015.08.047","article-title":"A histamine-independent itch pathway is required for allergic ocular itch","volume":"137","author":"Huang","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib102","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/s41591-018-0083-x","article-title":"Anatomical and functional dichotomy of ocular itch and pain","volume":"24","author":"Huang","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2023.08.017_bib103","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.neuroscience.2014.02.005","article-title":"Behavioral model of itch, alloknesis, pain and allodynia in the lower hindlimb and correlative responses of lumbar dorsal horn neurons in the mouse","volume":"266","author":"Akiyama","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/j.jaci.2023.08.017_bib104","doi-asserted-by":"crossref","DOI":"10.4161\/jkst.24137","article-title":"The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis","volume":"2","author":"Bao","year":"2013","journal-title":"JAK-STAT"},{"key":"10.1016\/j.jaci.2023.08.017_bib105","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/380630a0","article-title":"Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene","volume":"380","author":"Shimoda","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2023.08.017_bib106","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jaci.2022.12.802","article-title":"STAT6 gain-of-function variant exacerbates multiple allergic symptoms","volume":"151","author":"Takeuchi","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib107","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221755","article-title":"Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease","volume":"220","author":"Sharma","year":"2023","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2023.08.017_bib108","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaci.2022.09.028","article-title":"A germline STAT6 gain-of-function variant is associated with early-onset\u00a0allergies","volume":"151","author":"Suratannon","year":"2023","journal-title":"J Allergy Clin Immuno"},{"key":"10.1016\/j.jaci.2023.08.017_bib109","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jaci.2023.01.023","article-title":"Severe allergic dysregulation due to a gain of function mutation in the transcription factor STAT6","volume":"152","author":"Baris","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib110","doi-asserted-by":"crossref","unstructured":"Minskaia E, Maimaris J, Jenkins P, et\u00a0al. Autosomal dominant STAT6 gain of function causes severe atopy associated with lymphoma [e-pub ahead of print]. J Clin Immunol https:\/\/doi.org\/10.1007\/s10875-023-01530-7. Accessed July 11, 2023.","DOI":"10.21203\/rs.3.rs-2116300\/v1"},{"key":"10.1016\/j.jaci.2023.08.017_bib111","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.immuni.2022.09.016","article-title":"Interleukin-33-activated neuropeptide CGRP-producing memory Th2 cells cooperate with somatosensory neurons to induce conjunctival itch","volume":"55","author":"Okano","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2023.08.017_bib112","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1111\/j.1365-2222.2003.01782.x","article-title":"Differential in\u00a0vivo cytokine mRNA expression in lesional skin of intrinsic vs. extrinsic atopic dermatitis patients using semiquantitative RT-PCR","volume":"33","author":"Jeong","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2023.08.017_bib113","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jaci.2022.01.028","article-title":"Mechanistic insights into the antipruritic effects of lebrikizumab, an anti-IL-13 mAb","volume":"150","author":"Miron","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.696784","article-title":"Th2 modulation of transient receptor potential channels: an unmet therapeutic intervention for atopic dermatitis","volume":"12","author":"Meng","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib115","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/275661a0","article-title":"Release of vasoactive intestinal polypeptide in mast cells by histamine liberators","volume":"275","author":"Cutz","year":"1978","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2023.08.017_bib116","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/exd.14014","article-title":"Interaction of peripheral nerves and mast cells, eosinophils, and basophils in the development of pruritus","volume":"28","author":"Nakashima","year":"2019","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib117","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.2174\/138161209789105036","article-title":"Mast cells: target and source of neuropeptides","volume":"15","author":"Tore","year":"2009","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jaci.2023.08.017_bib118","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/exd.14182","article-title":"MRGPRX2 signals its importance in cutaneous mast cell biology: does MRGPRX2 connect mast cells and atopic dermatitis?","volume":"29","author":"Wang","year":"2020","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib119","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1111\/all.14213","article-title":"The pseudoallergen receptor MRGPRX2 on peripheral blood basophils and eosinophils: expression and function","volume":"75","author":"Wedi","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2023.08.017_bib120","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0923-1811(03)00004-5","article-title":"Serum levels of vasoactive intestinal peptide are elevated in patients with atopic dermatitis","volume":"31","author":"Umemoto","year":"2003","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2023.08.017_bib121","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.jid.2021.03.009","article-title":"Periostin, an emerging player in itch sensation","volume":"141","author":"Hashimoto","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib122","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn4819","article-title":"Miswiring of Merkel cell and pruriceptive C fiber drives the itch-scratch cycle","volume":"14","author":"Feng","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2023.08.017_bib123","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/exd.13945","article-title":"A novel player in the field: Merkel disc in touch, itch and pain","volume":"28","author":"Feng","year":"2019","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib124","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1038\/jid.2015.223","article-title":"Scratching induces overactivity in motor-related regions and reward system in chronic itch patients","volume":"135","author":"Mochizuki","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib125","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1126\/science.aar5703","article-title":"Piezo2 channel-Merkel cell signaling modulates the conversion of touch to itch","volume":"360","author":"Feng","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jaci.2023.08.017_bib126","doi-asserted-by":"crossref","first-page":"9975","DOI":"10.1038\/s41598-018-28195-2","article-title":"Somatosensory innervation of the oral mucosa of adult and aging mice","volume":"8","author":"Moayedi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2023.08.017_bib127","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41392-021-00646-9","article-title":"Inflammation, epigenetics, and metabolism converge to cell senescence and ageing: the regulation and intervention","volume":"6","author":"Zhu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jaci.2023.08.017_bib128","article-title":"Skin immunosenescence and type 2 inflammation: a mini-review with an inflammaging perspective","volume":"10","author":"Chen","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jaci.2023.08.017_bib129","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jaad.2015.11.029","article-title":"Immune dysregulation underlies a subset of patients with chronic idiopathic pruritus","volume":"74","author":"Xu","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib130","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/DAD.0000000000001902","article-title":"Chronic itch of unknown origin is associated with an enhanced Th2 skin immune profile","volume":"43","author":"Dehner","year":"2021","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaci.2023.08.017_bib131","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1468-3083.2012.04481.x","article-title":"Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients","volume":"27","author":"Iking","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2023.08.017_bib132","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2018.04.047","article-title":"Ethnic differences and comorbidities of 909 prurigo nodularis patients","volume":"79","author":"Boozalis","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib136","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40265-022-01741-z","article-title":"Nemolizumab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.jaci.2023.08.017_bib137","doi-asserted-by":"crossref","unstructured":"Yosipovitch, G. Mollenazar N, Stander S. Kwatra SG, Kim BS, Laws E, et\u00a0al. Dupilumab in adult patients with prurigo nodularis: results from two randomized phase 3 trials. Nat Med 2023;29:1180-90.","DOI":"10.1038\/s41591-023-02320-9"},{"key":"10.1016\/j.jaci.2023.08.017_bib138","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2023.08.017_bib139","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s13555-021-00630-9","article-title":"Dupilumab treatment provides sustained improvements over 2 years in symptoms and quality of life in adults with atopic dermatitis","volume":"11","author":"Yosipovitch","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaci.2023.08.017_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.156091","article-title":"IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling, and lung function decline","volume":"162","author":"Scott","year":"2023","journal-title":"Cytokine"},{"key":"10.1016\/j.jaci.2023.08.017_bib141","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jaci.2010.04.005","article-title":"Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma","volume":"125","author":"Busse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib142","doi-asserted-by":"crossref","first-page":"00576","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jaci.2023.08.017_bib143","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/all.15627","article-title":"IL-5 receptor expression in lung fibroblasts: potential role in airway remodeling in asthma","volume":"78","author":"Bajbouj","year":"2023","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2023.08.017_bib144","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.930862","article-title":"The therapeutic potential for targeting group 2 innate lymphoid cells in asthma","volume":"13","author":"Matsuyama","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib145","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.3390\/cells11233804","article-title":"IL-5 and GM-CSF, but not IL-3, promote the proliferative properties of inflammatory-like and lung resident-like eosinophils in the blood of asthma patients","volume":"11","author":"Palacionyte","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jaci.2023.08.017_bib146","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/cea.13885","article-title":"Treating severe asthma: targeting the IL-5 pathway","volume":"51","author":"Principe","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2023.08.017_bib147","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1111\/all.14791","article-title":"Interleukin-31: the \u201citchy\u201d cytokine in inflammation and therapy","volume":"76","author":"Datsi","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2023.08.017_bib148","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jaci.2018.09.011","article-title":"New aspects of neuroinflammation and neuroimmune crosstalk in the airways","volume":"142","author":"Nassenstein","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib149","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0026-22.2022","article-title":"Mapping of the sensory innervation of the mouse lung by specific vagal and dorsal root ganglion neuronal subsets","volume":"9","author":"Kim","year":"2022","journal-title":"eNeuro"},{"key":"10.1016\/j.jaci.2023.08.017_bib150","doi-asserted-by":"crossref","first-page":"L50","DOI":"10.1152\/ajplung.00376.2021","article-title":"Identification of lung innervating sensory neurons and their target specificity","volume":"322","author":"Su","year":"2022","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jaci.2023.08.017_bib151","doi-asserted-by":"crossref","first-page":"11515","DOI":"10.1073\/pnas.1411032111","article-title":"Population of sensory neurons essential for asthmatic hyperreactivity of inflamed airways","volume":"111","author":"Tr\u00e4nkner","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2023.08.017_bib152","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1398-9995.2007.01342.x","article-title":"Airway expression of calcitonin gene-related peptide in T-cell peptide-induced late asthmatic reactions in atopics","volume":"62","author":"Kay","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2023.08.017_bib153","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1164\/ajrccm\/151.3_Pt_1.613","article-title":"Elevated substance P content in induced sputum from patients with asthma\u00a0and\u00a0patients with chronic bronchitis","volume":"151","author":"Tomaki","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2023.08.017_bib154","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.coph.2009.02.002","article-title":"Role of TRPV1 in inflammation-induced airway hypersensitivity","volume":"9","author":"Lee","year":"2009","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jaci.2023.08.017_bib155","doi-asserted-by":"crossref","first-page":"9099","DOI":"10.1073\/pnas.0900591106","article-title":"sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma","volume":"106","author":"Caceres","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2023.08.017_bib156","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nature24029","article-title":"The neuropeptide NMU amplifies ILC2-driven allergic lung inflammation","volume":"549","author":"Wallrapp","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2023.08.017_bib157","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11882-020-00979-5","article-title":"Mast cell-specific MRGPRX2: a key modulator of neuro-immune interaction in allergic diseases","volume":"21","author":"Thapaliya","year":"2021","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaci.2023.08.017_bib158","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.immuni.2020.01.012","article-title":"Human mast cell proteome reveals unique lineage, putative functions, and structural basis for cell ablation","volume":"52","author":"Plum","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2023.08.017_bib159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-017-0698-3","article-title":"Upregulation of Mas-related G protein coupled receptor X2 in asthmatic lung mast cells and its activation by the novel neuropeptide hemokinin-1","volume":"19","author":"Manorak","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.jaci.2023.08.017_bib160","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.immuni.2019.06.009","article-title":"Neuropeptide CGRP limits group 2 innate lymphoid cell responses and constrains type 2 inflammation","volume":"51","author":"Nagashima","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2023.08.017_bib161","doi-asserted-by":"crossref","first-page":"L963","DOI":"10.1152\/ajplung.00130.2002","article-title":"Attenuation of antigen-induced airway hyperresponsiveness in CGRP-deficient mice","volume":"283","author":"Aoki-Nagase","year":"2002","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jaci.2023.08.017_bib162","article-title":"Manipulation of the inflammatory reflex as therapeutic strategy","volume":"3","author":"Kelly","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jaci.2023.08.017_bib163","article-title":"Periostin: contributor to abnormal airway epithelial function in asthma?","volume":"57","author":"Burgess","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2023.08.017_bib164","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/cei.13191","article-title":"Increased \u03b22-adrenoceptor phosphorylation in airway smooth muscle in severe asthma: possible role of mast cell-derived growth factors","volume":"194","author":"Chachi","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib165","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/JLB.3MR1117-426R","article-title":"Eosinophil and airway nerve interactions in asthma","volume":"104","author":"Drake","year":"2018","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaci.2023.08.017_bib166","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.devcel.2020.09.024","article-title":"Less is more: rare pulmonary neuroendocrine cells function as critical sensors in lung","volume":"55","author":"Xu","year":"2020","journal-title":"Dev Cell"},{"key":"10.1016\/j.jaci.2023.08.017_bib167","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41577-020-00477-9","article-title":"Regulation of immune responses by the airway epithelial cell landscape","volume":"21","author":"Hewitt","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib168","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat9453","article-title":"The cysteinyl leukotriene 3 receptor regulates expansion of IL-25\u2013producing airway brush cells leading to type 2 inflammation","volume":"3","author":"Bankova","year":"2018","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib169","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-immunol-042718-041505","article-title":"Tuft cells\u2014systemically dispersed sensory epithelia integrating immune and neural circuitry","volume":"37","author":"O'Leary","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib170","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.14425","article-title":"EEACI biologicals guidelines \u2013 recommendations for severe asthma","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2023.08.017_bib171","first-page":"CD003559","article-title":"Omalizumab for asthma in adults and children","volume":"13","author":"Normansell","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaci.2023.08.017_bib172","first-page":"CD010834","article-title":"Anti-IL5 therapies for asthma","volume":"9","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaci.2023.08.017_bib173","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.08.017_bib174","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-2600(22)00492-1","article-title":"Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomized, placebo-controlled extension study","volume":"11","author":"Menzies-Gow","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2023.08.017_bib175","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.08.017_bib176","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.08.017_bib177","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2023.08.017_bib178","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-pathol-052016-100401","article-title":"Immunopathogenesis of chronic rhinosinusitis and nasal polyposis","volume":"12","author":"Schleimer","year":"2017","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jaci.2023.08.017_bib179","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11882-016-0617-6","article-title":"Olfaction in chronic rhinosinusitis","volume":"16","author":"Rombaux","year":"2016","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaci.2023.08.017_bib180","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/00005537-200007000-00001","article-title":"Chronic sinusitis and anosmia: pathologic changes in the olfactory mucosa","volume":"110","author":"Kern","year":"2000","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2023.08.017_bib181","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/lary.28233","article-title":"Response to glucocorticosteroids predicts olfactory outcome after ESS in chronic rhinosinusitis","volume":"130","author":"Bogdanov","year":"2020","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaci.2023.08.017_bib182","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.2500\/ajra.2016.30.4279","article-title":"Evaluation of residual symptoms: a method to assess surgical outcomes for nasal polyposis","volume":"30","author":"Nguyen","year":"2016","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaci.2023.08.017_bib183","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/lio2.485","article-title":"Olfaction: sensitive indicator of inflammatory burden in chronic rhinosinusitis","volume":"5","author":"Yan","year":"2020","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"10.1016\/j.jaci.2023.08.017_bib184","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/j.1398-9995.2006.01225.x","article-title":"Differentiation of chronic sinus diseases by measurement of inflammatory mediators","volume":"61","author":"Van Zele","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2023.08.017_bib185","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.jaci.2013.12.1092","article-title":"Basophils are elevated in nasal polyps of patients with chronic rhinosinusitis without aspirin sensitivity","volume":"133","author":"Mahdavinia","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib186","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jaci.2012.02.046","article-title":"Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polyps","volume":"130","author":"Takabayashi","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib187","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1007\/s12070-017-1149-7","article-title":"Olfaction and its correlates in allergic rhinitis: a case control study","volume":"71","author":"Gupta","year":"2019","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jaci.2023.08.017_bib188","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib189","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2023.08.017_bib190","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2023.08.017_bib191","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomized, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.08.017_bib192","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jaip.2022.03.002","article-title":"Chronic rhinosinusitis with nasal polyps: quality of life in the biologics era","volume":"10","author":"Mullol","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.08.017_bib193","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jaip.2021.09.037","article-title":"Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps","volume":"10","author":"Mullol","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.08.017_bib194","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1056\/NEJM200408263510924","article-title":"Eosinophilic esophagitis","volume":"351","author":"Noel","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.08.017_bib195","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jama.2021.14920","article-title":"Eosinophilic esophagitis: a review","volume":"326","author":"Muir","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jaci.2023.08.017_bib196","doi-asserted-by":"crossref","first-page":"11","DOI":"10.21037\/tgh-22-15","article-title":"EoE behaves as a unique Th2 disease: a narrative review","volume":"8","author":"Rabinowitz","year":"2023","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib197","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.cgh.2021.11.002","article-title":"Esophageal dysmotility is associated with disease severity in eosinophilic esophagitis","volume":"20","author":"Carlson","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib198","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14475","article-title":"Association between eosinophilic esophagitis and esophageal dysmotility: a systematic review and meta-analysis","volume":"35","author":"Reddy","year":"2023","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.jaci.2023.08.017_bib199","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.anai.2022.10.026","article-title":"Breaking down the complex pathophysiology of eosinophilic esophagitis","volume":"130","author":"Underwood","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib200","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s40629-017-0037-8","article-title":"Current concepts in eosinophilic esophagitis","volume":"26","author":"Simon","year":"2017","journal-title":"Allergo J Int"},{"key":"10.1016\/j.jaci.2023.08.017_bib201","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1016\/j.celrep.2019.04.096","article-title":"An atlas of vagal sensory neurons and their molecular specialization","volume":"27","author":"Kupari","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.jaci.2023.08.017_bib202","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12016-018-8674-3","article-title":"Biological therapies for eosinophilic esophagitis: where do we stand?","volume":"55","author":"Ko","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib203","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaci.2011.11.044","article-title":"Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial","volume":"129","author":"Spergel","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib204","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.jaci.2023.08.017_bib206","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2014.07.049","article-title":"Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis","volume":"135","author":"Rothenberg","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib207","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1053\/j.gastro.2018.10.051","article-title":"RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis","volume":"156","author":"Hirano","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2023.08.017_bib208","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2023.08.017_bib209","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.08.017_bib210","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib211","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjd.15928","article-title":"Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement","volume":"178","author":"Drucker","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.017_bib212","author":"Global Initiative for Asthma"},{"key":"10.1016\/j.jaci.2023.08.017_bib213","first-page":"833","article-title":"Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma","volume":"22","author":"Dalal","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jaci.2023.08.017_bib214","doi-asserted-by":"crossref","first-page":"194","DOI":"10.21037\/tp-21-577","article-title":"Safety of corticosteroids in the treatment of acute respiratory disease in children: a systematic review and meta-analysis","volume":"11","author":"Yang","year":"2022","journal-title":"Transl Pediatr"},{"key":"10.1016\/j.jaci.2023.08.017_bib215","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.854","article-title":"Dupilumab provides rapid and sustained improvement in SCORing Atopic Dermatitis outcomes in paediatric patients with atopic dermatitis","volume":"102","author":"Wollenberg","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2023.08.017_bib216","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101826","article-title":"Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor \u03b2 antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study","volume":"57","author":"Sofen","year":"2023","journal-title":"EClinicalMed"},{"key":"10.1016\/j.jaci.2023.08.017_bib217","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v101.307","article-title":"Dupilumab provides rapid and sustained clinically meaningful responses in adults with moderate-to-severe atopic dermatitis","volume":"101","author":"Silverberg","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2023.08.017_bib218","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jaci.2022.12.824","article-title":"In search of the Holy Grail in atopic dermatitis: will dupilumab become the first disease-modifying atopic dermatitis drug?","volume":"151","author":"Bieber","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib219","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jaci.2022.08.026","article-title":"Attenuating the atopic march: meta-analysis of the dupilumab atopic dermatitis database for incident allergic events","volume":"151","author":"Geba","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.017_bib220","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s13555-022-00737-7","article-title":"Current and emerging strategies to inhibit type 2 inflammation in atopic dermatitis","volume":"12","author":"Haddad","year":"2022","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923010709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923010709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T12:34:20Z","timestamp":1729082060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674923010709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":216,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0091674923010709"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2023.08.017","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroimmune interplay during type 2 inflammation: Symptoms, mechanisms, and therapeutic targets in atopic diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2023.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}